Company intelligence / Profile preview

NERx Biosciences

Indianapolis, Indiana, USAnerxbiosciences.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

No clinical results yet; preliminary in vivo studies show limited toxicity for some compounds. The company is preparing for first-in-human trials targeting novel DDR proteins such as RPA.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

Ku inhibitor

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Indiana University School of Medicine research collaboration via co-founder Dr. John Turchi’s lab.Indiana Biosciences Research Institute membership and collaboration through Quantum Leap Award program, including access to Roche Diagnostics resources and IBRI facilities.

Beyond the preview

Go deeper on NERx Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NERx Biosciences.

Explore the full profile